Anika Therapeutics Inc. (ANIK) Is Sinking On Phase 3 Study Results
Anika Therapeutics Inc. (ANIK) announced after the bell Tuesday that its Phase 3 study of CINGAL 16-02 in patients with knee osteoarthritis failed to reach statistical significance in terms of the primary endpoint.
Source: RTTNews